Corporate | 29 July 2008 09:34
STRATEC Biomedical Systems AG / Alliance/Agreement
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
STRATEC, GREINER and MAVEN announce development cooperation for label-free
system solution
Birkenfeld, July 29, 2008
STRATEC Biomedical Systems AG, Birkenfeld, Germany, Greiner Bio-One GmbH,
Frickenhausen, Germany, and Maven Biotechnologies, Pasadena, CA, USA, have
signed their first agreement regarding a joint development program.
This joint development of system solutions is based on a state of the art
label-free detection technology for the diagnostics and pharmaceutical
industries. These systems will combine reliability of high quality results
with greatly reduced costs for laboratories and the industry.
This agreement marks a milestone in the development of each company as it
will combine expertise and technologies of three market leading companies
in a perfectly complementary market.
Based on their experience of developing and manufacturing high quality
analyzer systems for almost 30 years STRATEC will automate Maven’s
LFIRE™ label-free detection methods using Greiner’s disposable
technology featuring high optical performance.
Greiner has a proven track record of developing and producing medical
disposables combining high quality optical features with cost
effectiveness.
Maven’s label-free technology allows low to high density multiplexing for
real time kinetic or end-point analysis. This technology is expected to
gain significant market shares in the worldwide research and immunoassay
market. By obviating much of the costs and time-consuming steps associated
with traditionally labeled immunodiagnostics, and incorporating
simultaneous analysis of multiple biomarkers, LFIRE™ can provide a truly
cost effective enabling technology to meet the demands of personalized
medicine.
Each party will be entitled to use the new technology for future
developments and customer solutions.
About Greiner Bio-One GmbH – BioScience Division
Greiner Bio-One is specialised in the development, production and
distribution of plastic laboratory equipment. The company is technology
partner for universities, research institutes and the diagnostic,
pharmaceutical and biotechnology industries as well. With the BioScience
division, Greiner Bio-One ranks among the leading providers of specialised
products for the cultivation and analysis of cell and tissue cultures, as
well as microplates for high-throughput screening, allowing industry and
research most rapid and efficient drug screening. Additionally Greiner
Bio-One develops innovative biochip technologies for genotyping.
The German headquarters of the BioScience division in Frickenhausen
(Baden-Württemberg) controls the whole research and development activities
in the product ranges Cell Culture, High-Throughput Screening, Biochips and
OEM.
Greiner Bio-One GmbH is a division of Greiner Bio-One International AG,
based in Kremsmuenster (Austria). Today Greiner Bio-One International AG
generates a turnover of 241.7 million Euro. It has over 1,200 employees and
operates globally with 18 own subsidiaries and numerous distributors in
more than 100 countries.
About Maven Biotechnologies
Maven Biotechnologies, LLC is a privately held biotechnology company
located in Pasadena, CA, USA. It has developed the LFIRE™, a flexible, cost
effective, label-free, high density imaging system for quantitative
biomarker analysis that can characterize molecular binding reactions in
real-time. The platform has practical advantages over existing products
with applications in biomedical research, drug discovery, diagnostics,
biodefense, biological manufacturing, biochip quality control production
and other high growth fields. Maven's technology has great promise to
become a dominant technology platform for the new era of personalized
medicine. With secure intellectual property including a number of issued
patents and multiple pending patents, Maven is executing a multifaceted
development strategy.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated analyzer systems for its partners in the
fields of clinical diagnostics and biotechnology. These partners market
such systems, in general together with their own reagents, to laboratories,
blood banks and research institutes around the world. The company develops
its products on the basis of its own patented technologies. Shares in the
company (ISIN: DE0007289001) are traded in the Prime Standard segment of
the Frankfurt Stock Exchange.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email: ir@stratec-biomedical.de
29.07.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------